These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 25241887)

  • 21. Randomized comparison of sirolimus and paclitaxel drug-eluting stents for long lesions in the left anterior descending artery: an intravascular ultrasound study.
    Petronio AS; De Carlo M; Branchitta G; Papini B; Ciabatti N; Gistri R; Cortese B; Gherarducci G; Barsotti A
    J Am Coll Cardiol; 2007 Feb; 49(5):539-46. PubMed ID: 17276176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial (A Trial of Everolimus-Eluting Stents and Paclitaxel Stents for Coronary Revascularization in Daily Practice).
    Smits PC; Vlachojannis GJ; McFadden EP; Royaards KJ; Wassing J; Joesoef KS; van Mieghem C; van de Ent M
    JACC Cardiovasc Interv; 2015 Aug; 8(9):1157-1165. PubMed ID: 26210806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular responses to the multiple overlapped paclitaxel-eluting stents for the treatment of bare-metal in-stent restenotic lesions: angiographic and intravascular ultrasound analysis from the TAXUS-V ISR trial.
    Koizumi T; Fitzgerald PJ; Honda Y; Ellis SG; Kent K; Martin SL; Brown CL; Masud AR; Patterson JB; Greenberg J; Friedman M; Uchida T; Stone GW
    Cardiovasc Revasc Med; 2010; 11(3):140-8. PubMed ID: 20599163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
    Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vascular responses at proximal and distal edges of paclitaxel-eluting stents: serial intravascular ultrasound analysis from the TAXUS II trial.
    Serruys PW; Degertekin M; Tanabe K; Russell ME; Guagliumi G; Webb J; Hamburger J; Rutsch W; Kaiser C; Whitbourn R; Camenzind E; Meredith I; Reeves F; Nienaber C; Benit E; Disco C; Koglin J; Colombo A;
    Circulation; 2004 Feb; 109(5):627-33. PubMed ID: 14769685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized comparison of paclitaxel-eluting stents versus bare-metal stents for treatment of unprotected left main coronary artery stenosis.
    Erglis A; Narbute I; Kumsars I; Jegere S; Mintale I; Zakke I; Strazdins U; Saltups A
    J Am Coll Cardiol; 2007 Aug; 50(6):491-7. PubMed ID: 17678730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of drug-eluting stents on distal vessels.
    Wakabayashi K; Mintz GS; Weissman NJ; Stone GW; Ellis SG; Grube E; Ormiston JA; Turco MA; Pakala R; Xue Z; Desale S; Laynez-Carnicero A; Romaguera R; Sardi G; Pichard AD; Waksman R
    Circ Cardiovasc Interv; 2012 Apr; 5(2):211-9. PubMed ID: 22496083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel polymer-free paclitaxel-eluting stent with a nanoporous surface for rapid endothelialization and inhibition of intimal hyperplasia: Comparison with a polymer-based sirolimus-eluting stent and bare metal stent in a porcine model.
    Jia H; Liu H; Kong J; Hou J; Wu J; Zhang M; Tian J; Liu H; Ma L; Hu S; Huang X; Zhang S; Zhang S; Yu B; Jang IK
    J Biomed Mater Res A; 2011 Sep; 98(4):629-37. PubMed ID: 21732525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravascular ultrasound findings in patients with restenosis of sirolimus- and paclitaxel-eluting stents.
    Ohlmann P; Mintz GS; Kim SW; Pichard AD; Satler LF; Kent KM; Suddath WO; Waksman R; Weissman NJ
    Int J Cardiol; 2008 Mar; 125(1):11-5. PubMed ID: 17442432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multicenter randomized trial comparing amphilimus- with paclitaxel-eluting stents in de novo native coronary artery lesions.
    Carrié D; Berland J; Verheye S; Hauptmann KE; Vrolix M; Violini R; Dibie A; Berti S; Maupas E; Antoniucci D; Schofer J
    J Am Coll Cardiol; 2012 Apr; 59(15):1371-6. PubMed ID: 22284328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of edge effects with paclitaxel-eluting stents using serial intravascular ultrasound radiofrequency data analysis: the BETAX (BEside TAXus) Study.
    García-García HM; Gonzalo N; Tanimoto S; Meliga E; de Jaegere P; Serruys PW
    Rev Esp Cardiol; 2008 Oct; 61(10):1013-9. PubMed ID: 18817677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An integrated TAXUS IV, V, and VI intravascular ultrasound analysis of the predictors of edge restenosis after bare metal or paclitaxel-eluting stents.
    Liu J; Maehara A; Mintz GS; Weissman NJ; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Stone GW
    Am J Cardiol; 2009 Feb; 103(4):501-6. PubMed ID: 19195510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravascular ultrasound results from the NEVO ResElution-I trial: a randomized, blinded comparison of sirolimus-eluting NEVO stents with paclitaxel-eluting TAXUS Liberté stents in de novo native coronary artery lesions.
    Otake H; Honda Y; Courtney BK; Shimohama T; Ako J; Waseda K; Macours N; Rogers C; Popma JJ; Abizaid A; Ormiston JA; Spaulding C; Cohen SA; Fitzgerald PJ
    Circ Cardiovasc Interv; 2011 Apr; 4(2):146-54. PubMed ID: 21386089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of attenuated-signal plaque observed by intravascular ultrasound on vessel response after drug-eluting stent implantation.
    Kitahara H; Waseda K; Sakamoto K; Yamada R; Huang CC; Nakatani D; Sakata K; Kawarada O; Yock PG; Matsuyama Y; Yokoi H; Nakamura M; Muramatsu T; Nanto S; Fitzgerald PJ; Honda Y
    Atherosclerosis; 2017 Apr; 259():68-74. PubMed ID: 28327450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravascular ultrasound findings of stent fractures in patients with Sirolimus- and Paclitaxel-eluting stents.
    Doi H; Maehara A; Mintz GS; Tsujita K; Kubo T; Castellanos C; Lansky AJ; Witzenbichler B; Guagliumi G; Brodie B; Kellett MA; Parise H; Mehran R; Leon MB; Moses JW; Stone GW
    Am J Cardiol; 2010 Oct; 106(7):952-7. PubMed ID: 20854956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
    El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
    Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial.
    Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G; De Luca G
    Am Heart J; 2009 Oct; 158(4):e43-50. PubMed ID: 19781402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence, mechanisms, predictors, and clinical impact of acute and late stent malapposition after primary intervention in patients with acute myocardial infarction: an intravascular ultrasound substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial.
    Guo N; Maehara A; Mintz GS; He Y; Xu K; Wu X; Lansky AJ; Witzenbichler B; Guagliumi G; Brodie B; Kellett MA; Dressler O; Parise H; Mehran R; Stone GW
    Circulation; 2010 Sep; 122(11):1077-84. PubMed ID: 20805433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Leon MB; Kandzari DE; Eisenstein EL; Anstrom KJ; Mauri L; Cutlip DE; Nikolsky E; O'Shaughnessy C; Overlie PA; Kirtane AJ; McLaurin BT; Solomon SL; Douglas JS; Popma JJ;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1208-18. PubMed ID: 20129547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.